

IDMP PMS TOM

16th October 2019

Industry Perspectives

Industry Concept Paper

- The Case for an Integrated Approach with SPOR
 - Developed by Industry Trade Associations (*endorsed by EFPIA, AESGP, MfE and EuropaBio*)
 - Sent to EMA and TMB end July – still awaiting a response
- Topics addressed
 - Need for **data quality** to serve **multiple use cases** (i.e. more than PV)
 - **Submit data once, assess by relevant CA**, store and reuse
 - Reinforce Industry support for **first TOM phase** starting at PMS go live
 - **No Industry support for current Article 57 process**
 - Promote an **end-to-end** program covering SPOR/IDMP, TOM and NVR

Setting the scene: IDMP Timelines

- Human Domain (IDMP/PMS)

- Required in Regulation by:
- IDMP/SPOR Task Force in May 2019:
 - Go Live (can submit to PMS):
 - Enforcement (must submit):

July 2016


Q3 2021

Q3 2022

- Veterinary Domain (NVR/UPD)

- Required in Regulation by:

January 2022



Target Operating Model

- Current Article 57 process known to lead to data quality issues
 - Review of data **post-approval**, performed by **EMA**, based on **labeling** documents
- All willing to implement the TOM (EMA, NCAs, Industry)
 - Review of data **during approval**, performed by **relevant CA**, based on **Module 3** (where relevant)
- Need **pragmatic** approach and **agreement** within Regulatory Network
 - **Phased** TOM approach
 - **Limited process disruption** from NCA perspective
 - **Decision/endorsement** by TMB before end 2019
 - TOM **Business Case** for TOM Phasing to present at **EU TMB** on **7-Nov-2019**

TOM Implementation – CESSP Approach



- CESSP Phases

Phase	Date	Dataset Module	Human	Vet
1	Q2 2020	▪ Initial MAA	▪ based on DES	▪ based on DES
2	Q4 2020	▪ Initial MAA ▪ Variation/Renewal	▪ based on DES ▪ -	▪ based on FHIR ▪ based on FHIR
3	Q3 2021	CESSP HA Extensions to support TOM		
4	Q1 2022	▪ Initial MAA ▪ Variation/Renewal	▪ based on FHIR ▪ based on FHIR	▪ based on FHIR ▪ based on FHIR
5	Q4 2022	CESSP Finalization H&V and HA Features		

- Would bring IDMP PMS timelines to

- Go Live (optional): **Q1 2023** at earliest
- Enforcement (mandatory): **Q1 2024** at earliest

Feedback

- *Aggressive/Optimistic Timelines*
- *Industry Funding won't change Timelines*

TOM Implementation – EMA ‘fallback’ proposal

as we heard at the May Task Force

- **Phased Approach**

- Start with **IDMP compliance through PMS only**, full TOM gets added later when CESSP is ready
 - IDMP go-live with PMS within announced timelines (2021-2022)
 - TOM-like assessment process is possible for CP only
- No **project dependency** on CESSP (assuming TOM needs CESSP)
- Assumption that TOM will be implemented #-years after (requires timeline **commitment**)

- **Initial phase details**

- No full TOM, due to no extended CESSP
- Partial TOM **for Centralized Procedure** (i.e. data assessment during procedure), enabled through procedure by the EMA within PMS
 - Source of truth for DQ assessment: Module 3 where applicable plus other documents incl. Labelling
- Submit product data through PMS API (or PMS UI) directly to PMS database

Risks and benefits

	Benefits	Risks
CESSP/TOM Approach	▪ Data based on Module 3 and SmPC ▪ Assessment during Procedure for EMA ▪ Assessment during Procedure for NCAs ▪ Full benefits of TOM at Go Live ▪ Support additional use cases (Type IA variation simplification, ePI, FMD...)	▪ Delay Go Live to after 2023 ▪ Risk to disengage EMA/Industry ▪ EU IG ready in 2020 – difficult to wait ▪ Keep XEVMPD for longer than expected ▪ Need to manage dependencies between PMS, NVR and CESSP, incl. governance and funding
EMA Fallback Approach	▪ Data based on Module 3 and SmPC ▪ Assessment during Procedure for EMA ▪ Limited benefits of TOM at Go Live ▪ Shortly abandon XEVMPD ▪ Rather independent start of PMS with regards to NVR and CESSP	▪ Assessment after Approval for NCAs ▪ Benefits of TOM in phased approach ▪ Delay to implement CESSP ▪ Risk to disengage NCAs ▪ Risk to stay with Phase 1

Industry Proposed Option Forward 1/2

- Pre-requisites/quick wins
 - Connect OMS with EudraGMDP for Manufacturers – needed to replace Type IA variations
- **ALL Procedure Types** (single process for Industry)
 - Industry to submit product data to PMS during procedure time
- **Centralized Procedure**
 - EMA/NCAs to review PMS data during procedure (TOM) based on PMS database
 - Start with to review PMS data and the Dossier under CP
 - Pilot data-only changes to the Dossier under CP (to replace Type IA variations)
 - Likely to require to submit and check baseline before supporting replacement of Type IA variations
- **MRP/DCP/NP**
 - Data is already in PMS at the time of submission, but will be reviewed by EMA only post-approval (to support PV use case)
 - Simplification of Type IA variations to be an incentive for NCAs to join TOM

Industry Proposed Option Forward 2/2

- Requirements/Expectations
 - Need HMA approval on the option forward
 - Need commitment from NCAs to join TOM for MRP/DCP/NP within defined timelines
- Expected Benefits
 - Better quality for PMS data (under CP at first)
 - Single process for CP/MRP/DCP/NP (at procedure time) – whatever the review process
 - As today for MRP/DCP/NP with more data
 - Including possibility for NCAs to pilot TOM
 - All progress on PMS will strengthen RMS, OMS and SMS
 - In addition to Industry willing to lead KUG efforts
 - Despite the strong & idealistic Industry Concept Paper position statements, **Industry members also want to be pragmatic and are ready to defend** the adoption of a first phase of PMS & TOM for CP only as a step towards full TOM implementation, **under certain conditions**
 - Use cases beyond PV...
 - Commitment to enable full TOM within defined timeframe

Phased Approach

